No­var­tis throws Cerulean a life­line with $5M deal; Porges diss­es Cel­gene’s GED-0301

No­var­tis has come along with a com­pa­ny-sav­ing deal to part­ner with Cerulean $CERU. Blast­ed by a re­cent tri­al fail­ure, the Waltham, MA-based biotech is pick­ing up a $5 mil­lion up­front to use its nanopar­ti­cle drug con­ju­gate tech with sev­er­al of No­var­tis’s drug can­di­dates. The deal al­so in­cludes po­ten­tial mile­stones on up to five tar­gets. Cerulean’s shares blast­ed up 60%, break­ing out of per­ilous pen­ny stock ter­ri­to­ry this morn­ing. Cerulean has al­so struck a deal to sell shares to As­pire Cap­i­tal Fund un­der a stock pur­chase agree­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER